Progyny, Inc. (NASDAQ:PGNY) Receives $33.25 Average Target Price from Analysts

Progyny, Inc. (NASDAQ:PGNY) has earned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $34.20.

PGNY has been the subject of several analyst reports. Citizens Jmp increased their price target on shares of Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research note on Monday, May 11th. Canaccord Genuity Group set a $35.00 price target on shares of Progyny in a research report on Friday. Truist Financial upped their price objective on Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a report on Monday, June 22nd. KeyCorp lifted their target price on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Finally, Bank of America increased their price target on Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd.

Insider Buying and Selling

In other news, Director Cheryl Scott sold 7,439 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $26.39, for a total value of $196,315.21. Following the sale, the director directly owned 19,772 shares of the company’s stock, valued at approximately $521,783.08. The trade was a 27.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kevin K. Gordon sold 5,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total transaction of $137,445.00. Following the completion of the sale, the director directly owned 9,318 shares in the company, valued at $232,856.82. This trade represents a 37.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,916 shares of company stock valued at $939,875 over the last three months. Company insiders own 9.90% of the company’s stock.

Hedge Funds Weigh In On Progyny

Hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System raised its position in Progyny by 0.7% in the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after purchasing an additional 457 shares during the period. Teza Capital Management LLC boosted its position in shares of Progyny by 5.4% during the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after buying an additional 516 shares during the period. Aristides Capital LLC grew its stake in shares of Progyny by 4.6% in the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after buying an additional 528 shares in the last quarter. Oxford Asset Management LLP grew its stake in shares of Progyny by 4.3% in the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after buying an additional 531 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Progyny by 3.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 19,202 shares of the company’s stock valued at $493,000 after buying an additional 637 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported second-quarter earnings of $0.55 per share, well above the $0.33 consensus estimate, while revenue of $350.5 million modestly exceeded expectations of $348.6 million. Revenue increased 5.3% year over year, and earnings improved from $0.19 per share in the prior-year quarter. Progyny Announces Second Quarter 2026 Results
• Positive Sentiment: Full-year 2026 adjusted EPS guidance of $2.04 to $2.10 is above the analyst consensus of $1.86, signaling confidence in profitability. Full-year revenue guidance of approximately $1.4 billion is broadly in line with expectations. Progyny Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: CEO Pete Anevski is scheduled to present at the Canaccord Genuity Annual Growth Conference on August 11. The event could provide additional detail on client demand, growth initiatives and the company’s outlook, but it does not immediately change financial results. Progyny to Present at Canaccord Genuity Conference
• Negative Sentiment: Third-quarter revenue guidance of $335 million to $345 million is below the $350.2 million analyst consensus. Although projected EPS of $0.50 to $0.52 exceeds the $0.47 consensus, investors appear more concerned about slower top-line momentum and the possibility that growth remains muted. Why Progyny Shares Are Sliding Today

Progyny Trading Down 7.0%

Shares of PGNY opened at $28.10 on Friday. Progyny has a 12-month low of $16.10 and a 12-month high of $33.06. The firm has a market capitalization of $2.20 billion, a P/E ratio of 30.54, a P/E/G ratio of 2.23 and a beta of 1.01. The firm has a 50-day moving average price of $29.08 and a 200 day moving average price of $23.43.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.46 million. Progyny had a net margin of 6.00% and a return on equity of 15.57%. Progyny’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.17 earnings per share. Equities research analysts predict that Progyny will post 1.19 earnings per share for the current fiscal year.

Progyny announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.